Asparagine: a metabolite to be targeted in cancers
J Jiang, S Batra, J Zhang - Metabolites, 2021 - mdpi.com
Amino acids play central roles in cancer progression beyond their function as building
blocks for protein synthesis. Thus, targeting amino acid acquisition and utilization has been …
blocks for protein synthesis. Thus, targeting amino acid acquisition and utilization has been …
Asparaginase pharmacology: challenges still to be faced
C Lanvers-Kaminsky - Cancer chemotherapy and pharmacology, 2017 - Springer
Purpose The benefits of asparaginase (ASNASE) in the treatment of ALL and NHL are
indisputable and new ASNASE preparations are under clinical development to overcome …
indisputable and new ASNASE preparations are under clinical development to overcome …
L-asparaginase immobilization in supramolecular nanogels of PEG-grafted poly HPMA and bis (α-cyclodextrin) to enhance pharmacokinetics and lower enzyme …
L-asparaginase (ASNase) enzyme has limited therapeutic use due to its poor
pharmacokinetics and immunogenicity. To overcome these obstacles, we immobilized …
pharmacokinetics and immunogenicity. To overcome these obstacles, we immobilized …
ALL blasts drive primary mesenchymal stromal cells to increase asparagine availability during asparaginase treatment
M Chiu, G Taurino, E Dander, D Bardelli… - Blood …, 2021 - ashpublications.org
Mechanisms underlying the resistance of acute lymphoblastic leukemia (ALL) blasts to l-
asparaginase are still incompletely known. Here we demonstrate that human primary bone …
asparaginase are still incompletely known. Here we demonstrate that human primary bone …
A protease-resistant Escherichia coli asparaginase with outstanding stability and enhanced anti-leukaemic activity in vitro
L-Asparaginases (ASNases) have been used as first line drugs for paediatric Acute
Lymphoblastic Leukaemia (ALL) treatment for more than 40 years. Both the Escherichia coli …
Lymphoblastic Leukaemia (ALL) treatment for more than 40 years. Both the Escherichia coli …
Asparaginase-phage P22 nanoreactors: toward a biobetter development for acute lymphoblastic Leukemia treatment
C Díaz-Barriga, F Villanueva-Flores, K Quester… - Pharmaceutics, 2021 - mdpi.com
Asparaginase (ASNase) is a biopharmaceutical for Acute Lymphoblastic Leukemia (ALL)
treatment. However, it shows undesirable side effects such as short lifetimes, susceptibility to …
treatment. However, it shows undesirable side effects such as short lifetimes, susceptibility to …
Low bioavailability and high immunogenicity of a new brand of E. coli L-asparaginase with active host contaminating proteins
PP Zenatti, NA Migita, NM Cury, RA Mendes-Silva… - …, 2018 - thelancet.com
The drug l-asparaginase is a cornerstone in the treatment of acute lymphoblastic leukemia
(ALL). The native E. coli l-asparaginase used in Brazil until recently has been manufactured …
(ALL). The native E. coli l-asparaginase used in Brazil until recently has been manufactured …
[HTML][HTML] Hypersensitivity reactions to asparaginase in mice are mediated by anti-asparaginase IgE and IgG and the immunoglobulin receptors FcεRI and FcγRIII
Asparaginase is an important drug for the treatment of leukemias. However, anti-
asparaginase antibodies often develop, which can decrease asparaginase drug levels and …
asparaginase antibodies often develop, which can decrease asparaginase drug levels and …
[HTML][HTML] Individualized dosing guidelines for PEGasparaginase and factors influencing the clearance: a population pharmacokinetic model
RQH Kloos, R Mathôt, R Pieters, IM van der Sluis - Haematologica, 2021 - ncbi.nlm.nih.gov
Considerable inter-and intra-patient variability exist in serum activity levels of
PEGasparaginase, essential for pediatric acute lymphoblastic leukemia (ALL) treatment. A …
PEGasparaginase, essential for pediatric acute lymphoblastic leukemia (ALL) treatment. A …
Asparaginase activities during intensified treatment with pegylated E. coli asparaginase in adults with newly-diagnosed acute lymphoblastic leukemia
C Lanvers-Kaminsky, A Niemann… - Leukemia & …, 2020 - Taylor & Francis
The GMALL07/2003 protocol introduced pegylated E. coli asparaginase (PEG-ASNase)
frontline for adults with acute lymphoblastic leukemia (ALL). PEG-ASNase (500 U/m2, 1000 …
frontline for adults with acute lymphoblastic leukemia (ALL). PEG-ASNase (500 U/m2, 1000 …